Developing an Oral Medicine for Alzheimer's Disease
GMP Production and Extended Toxicology of an Oral Formulation Drug for Alzheimer's Disease
['FUNDING_U01'] · NORTHWESTERN UNIVERSITY · NIH-11094088
This project is preparing an existing medicine, previously used for acute brain injuries, to be tested as a new oral treatment for Alzheimer's disease.
Quick facts
| Phase | ['FUNDING_U01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | NORTHWESTERN UNIVERSITY (nih funded) |
| Locations | 1 site (CHICAGO, UNITED STATES) |
| Trial ID | NIH-11094088 on ClinicalTrials.gov |
What this research studies
We are working to develop a new oral medicine for Alzheimer's disease by adapting a drug called MW189, which has already shown promise in treating acute brain injuries. This medicine works by calming down certain stress responses in the brain that contribute to memory loss and nerve damage. Our goal is to ensure this oral formulation is safe and ready for future testing in people living with Alzheimer's disease. By using a medicine that has already been studied, we hope to speed up the process of finding new treatments.
Who could benefit from this research
Good fit: Patients with Alzheimer's disease or related dementias may be ideal candidates for future clinical trials involving this medicine.
Not a fit: Patients without Alzheimer's disease or related dementias would likely not receive direct benefit from this specific treatment.
Why it matters
Potential benefit: If successful, this medicine could offer a new way to slow down or prevent the progression of Alzheimer's disease by targeting specific brain inflammation.
How similar studies have performed: The drug MW189 is currently in Phase 2 clinical testing for acute brain injuries, suggesting prior success in human studies for a different condition, and this approach of repurposing existing drugs is a recognized strategy.
Where this research is happening
CHICAGO, UNITED STATES
- NORTHWESTERN UNIVERSITY — CHICAGO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: WATTERSON, DANIEL MARTIN — NORTHWESTERN UNIVERSITY
- Study coordinator: WATTERSON, DANIEL MARTIN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Alzheimer disease dementia, Alzheimer syndrome, Alzheimer's Disease, Alzheimer's disease and related dementia